Demographics and clinical variables (N,%) unless otherwise specified | |
---|---|
Age (mean, SD) | 50.22 (14.17) |
Female | 198 (55) |
Marital status | |
Single | 64 (17.8) |
Married | 296 (82.2) |
Current smoker | 250 (69.4) |
Alcohol consumption | |
Abstainer | 256 (71.1) |
Drinker | 102 (28.3) |
Lebanese governorate | |
Beirut | 126 (35) |
Bekaa | 93 (25.8) |
Mount Lebanon | 85 (23.6) |
North Lebanon | 27 (7.5) |
Nabatiye | 15 (4.2) |
South Lebanon | 14 (3.9) |
Comorbidities | |
Diabetes mellitus | 110 (30.6) |
Anxiety | 108 (30) |
Depression | 24 (9.4) |
First-line agents | |
Any | 278 (77.2) |
Pregabalin | 218 (60.5) |
Gabapentin | 48 (13.3) |
Tricyclic antidepressants | 6 (1.7) |
Duloxetine | 4 (1.1) |
Venlafaxine | 2 (0.6) |
Second-line agents | |
Tramadol | 57 (15.8) |
Other agents | |
NSAIDs | 169 (46.8) |
Topical agents (Capsaicin, Lidocaine) | 20 (5.5) |
The most common drug combination used to treat neuropathic pain disorders | |
Dual: Gabapentinoids + NSAIDS | 78 (21.6) |
Gabapentinoids + Tramadol | 32 (8.9) |
Triple: Gabapentinoids + NSAIDS + Tramadol | 22 (6.1) |
Quadruple: Gabapentinoids + NSAIDS + Tramadol + topical agents | 18 (5) |
Medication dispensing | |
Prescription (orthopedist, neurologist, neurosurgeon) | 300 (83.5) |
No prescription | 60 (16.5) |
Medication utilization duration | |
< 1 month | 40 (11.1) |
< 6 months | 132 (36.7) |
6 months–1 year | 94 (26.1) |
> 1 year | 94 (26.1) |